4-[(4-Methylpiperazin-1-yl)methyl]benzohydrazide | 1236355-89-7

• 物质功能分类: 有机原料 - 肼或胲的有机衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[(4-Methylpiperazin-1-yl)methyl]benzohydrazide
• CAS: 1236355-89-7
• 化学式: C₁₃H₂₀N₄O
• mdl: MFCD19024292
• 分子量: 248.328
• InChiKey: IQFDROXROHQGEH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  61.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  cycloheptatriene-maleic anhydride adduct 、 4-[(4-Methylpiperazin-1-yl)methyl]benzohydrazide 在 N,N-二异丙基乙二胺 作用下， 以 乙醇 为溶剂， 反应 6.0h， 生成 N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2-(1H)-yl)-4-(4-methylpiperazin-1-methyl)benzamide
  参考文献：
  名称：

  Tricyclononene carboxamide derivatives as novel anti-HIV-1 agents

  摘要：

  By modifying the chemical structure of anti-orthopoxvirus compound ST-246, we designed and synthesized a series of tricyclononene carboxamide derivatives and tested their anti-HIV-1 activity and cytotoxicity. We found that benzoimidazol-containing compound 7g was highly effective in inhibiting HIV-1 R5 infection with an IC50 value of 0.41 mu M and a selectivity index of 292, but it exhibited no significant inhibitory activity on HIV-1 reverse transcriptase, integrase and protease. CoMFA was used to analyze structure-activity relationships with good predictive power (r(2) = 0.921; q(2) = 0.582). Moreover, the CoMFA model showed that the length of the molecule, the amide, and the amine moieties all played crucial roles in anti-HIV activity. These results suggest that 7g may serve as a lead for the development of novel anti-HIV-1 therapies. (C) 2010 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2010.05.070
• 作为产物：
  描述：

  4-[(4-甲基哌嗪-1-基)甲基]苯甲酸甲酯 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 4-[(4-Methylpiperazin-1-yl)methyl]benzohydrazide
  参考文献：
  名称：

  Tricyclononene carboxamide derivatives as novel anti-HIV-1 agents

  摘要：

  By modifying the chemical structure of anti-orthopoxvirus compound ST-246, we designed and synthesized a series of tricyclononene carboxamide derivatives and tested their anti-HIV-1 activity and cytotoxicity. We found that benzoimidazol-containing compound 7g was highly effective in inhibiting HIV-1 R5 infection with an IC50 value of 0.41 mu M and a selectivity index of 292, but it exhibited no significant inhibitory activity on HIV-1 reverse transcriptase, integrase and protease. CoMFA was used to analyze structure-activity relationships with good predictive power (r(2) = 0.921; q(2) = 0.582). Moreover, the CoMFA model showed that the length of the molecule, the amide, and the amine moieties all played crucial roles in anti-HIV activity. These results suggest that 7g may serve as a lead for the development of novel anti-HIV-1 therapies. (C) 2010 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2010.05.070

文献信息

• HDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation
  作者：Yufeng Xiao、Seth Hale、Nikee Awasthee、Chengcheng Meng、Xuan Zhang、Yi Liu、Haocheng Ding、Zhiguang Huo、Dongwen Lv、Weizhou Zhang、Mei He、Guangrong Zheng、Daiqing Liao

  DOI：10.1016/j.chembiol.2023.07.010

  日期：2023.11

  chimeras (PROTACs) can selectively degrade a target enzyme, abolishing both enzymatic and scaffolding function. Here, we report a novel HDAC3/8 dual degrader YX968 that induces highly potent, rapid, and selective degradation of both HDAC3/8 without triggering pan-HDAC inhibitory effects. Unbiased quantitative proteomic experiments confirmed its high selectivity. HDAC3/8 degradation by YX968 does not induce

  HDAC3 和 HDAC8 具有关键的生物学功能，是备受追捧的治疗靶点。由于组蛋白脱乙酰酶 （HDAC） 具有非常保守的催化结构域，因此开发同工酶选择性抑制剂仍然具有挑战性。HDAC3/8 还具有脱乙酰酶非依赖性活性，这是常规酶抑制剂无法阻断的。蛋白水解靶向嵌合体 （PROTAC） 可以选择性地降解靶酶，从而消除酶和支架功能。在这里，我们报道了一种新型 HDAC3/8 双重降解剂 YX968，它诱导两种 HDAC3/8 的高效、快速和选择性降解，而不会触发泛 HDAC 抑制作用。无偏倚的定量蛋白质组学实验证实了其高选择性。YX968 降解 HDAC3/8 不会诱导组蛋白高乙酰化和广泛的转录组扰动。因此，组蛋白高乙酰化可能是改变转录的主要因素。YX968 促进细胞凋亡并杀死癌细胞，在 体外具有高效效力。因此，YX968 代表了一种用于剖析 HDAC3/8 复杂生物学功能的新探针。
• [EN] SALINOMYCIN DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE LA SALINOMYCINE ET LEURS UTILISATIONS
  申请人：[en]HILLSTREAM BIOPHARMA, INC.

  公开号：WO2022187849A1

  公开（公告）日：2022-09-09

  The present invention provides compounds, compositions thereof, and methods of using the same.